Glad to see initiatives like these receiving some attention again. There has been a trend of narrowing focus exclusively fixated on vaccines - despite the evid

Glad to see initiatives like these receiving some attention again. There has been a trend of narrowing focus exclusively fixated on vaccines - despite the evidence that combinations of existing medicines can greatly reduce the risk of hospitalization and death, especially when COVID-19 patients are treated early [1][2]. The key is that many previous studies evaluated the effectiveness of specific drugs in a standalone regime. However a multidrug approach based on antibiotics, corticosteroids, and antithrombotics - and delivered early on in the symptomatic phase of illness - has tremendous potential to reduce poor health outcomes due to SARS-CoV-2 infection. Although the OP does not specifically mention this exact approach, this is a step in the right direction. [1] Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection https://www.amjmed.com/article/S0002-9343(20)30673-2/fulltext https://www.amjmed.com/article/S0002-9343(20)30673-2/fulltex... [2] Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19) https://scholarlycommons.henryford.com/cgi/viewcontent.cgi?article=1139&context=infectiousdiseases_articles https://scholarlycommons.henryford.com/cgi/viewcontent.cgi?a...